Thymosin α-1

Thymosin α-1 is a 28-amino-acid acidic peptide first isolated from the thymus and now produced synthetically as thymalfasin. It is an immunomodulator rather than an immunostimulant — the published activity profile is heterogeneous across cell types, with effects on T-cell maturation and differentiation, dendritic-cell function, natural killer cell activity, regulatory cytokine balance, and TLR-mediated innate immune signaling ([Dominari et al., *World J Virol* 2020, 9:67–78](https://doi.org/10.5501/wjv.v9.i5.67)). The clinical development arc has tracked these mechanisms: early use in chronic viral hepatitis (where T-cell exhaustion is part of the disease biology), expansion into sepsis and severe infections, adjuvant use with vaccines in immunosenescent populations, and most recently a wave of interest in long-COVID and post-viral immune dysregulation. The peptide does not act through a single receptor pathway; it is best understood as a fine-tuning agent for the adaptive immune system rather than a directional stimulant.

Thymosin α-1 has more cumulative human exposure than any peptide on this site by a wide margin. Approved in over 35 countries — across the European Union, much of Asia, and parts of Latin America — under the trade name Zadaxin (or Thymalfasin), it has been in routine clinical use for chronic hepatitis B and as an adjunct for chronic hepatitis C and selected immunodeficiency conditions for roughly three decades. The clinical evidence base is therefore unusually substantial for a peptide on this list: multiple randomized controlled trials in chronic hepatitis B (the Andreone trials in *Journal of Hepatology* in the late 1990s and 2000s among the better-known examples), pooled-trial analyses in HCV, and observational evidence across sepsis adjunct use have all been published in mainstream journals. The evidence is real and uneven. The hepatitis B and C indications are where the historical clinical use sits, but the comparative efficacy of thymosin α-1 versus interferon-based or direct-acting antiviral regimens is mixed across trials and largely surpassed by the modern direct-acting antiviral era for hepatitis C. In sepsis adjunct and post-operative immune-support settings the data is supportive but heterogeneous, with effect sizes that vary by population, dose, and timing of administration. The most prominent recent renewal of interest came during COVID-19, when small clinical studies (including the much-cited Wuhan cohort reported in 2020) suggested benefits in lymphopenia and T-cell preservation in severely ill patients; long-COVID and post-viral immune dysregulation are now the leading edge of new research. The honest framing balances exposure with mixed efficacy. Thymosin α-1 has the deepest tolerability record on this site. It is also one of the few peptides where biohacker use roughly mirrors actual clinical indications — immune support during recovery from infection, pre- or post-surgical immune support, and long-COVID — rather than diverging from them. The trade-off is that the magnitude of effect across these uses is more variable than the marketing of the molecule sometimes suggests.